Yuan-Tso Cheng
Overview
Explore the profile of Yuan-Tso Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung Y, Huang G, Kang C, Cheng Y, Kao Y, Chien Y
Lab Invest
. 2023 Mar;
103(7):100131.
PMID: 36948295
Renal fibrosis is a hallmark of chronic and progressive renal diseases characterized by excessive fibroblast proliferation, extracellular matrix accumulation, and a loss of renal function, eventually leading to end-stage renal...
2.
Chiang P, Chiang P, Chen I, Chen Y, Wang H, Cheng Y, et al.
Medicine (Baltimore)
. 2023 Feb;
102(5):e32671.
PMID: 36749250
While radium (Ra)-223 is among the multiple, known life-prolonging treatments in bone-predominant metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequencing has not been determined, particularly in the Asia-Pacific context. Hence,...
3.
Huang G, Huang C, Kang C, Cheng Y, Tsai P, Kao Y, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675289
Upper tract urothelial cancer (UTUC) is a less common disease in Western countries but has a high level of prevalence in Asian populations. Compared to bladder cancer, unique etiologic and...
4.
Huang Y, Wang H, Sung M, Chuang Y, Chen Y, Cheng Y, et al.
Front Oncol
. 2022 Dec;
12:1031774.
PMID: 36530967
Purpose: To evaluate the prognostic impact of the lowest level of tumor location for upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). Materials And Methods: Data were collected...
5.
Lee W, Wu K, Tain Y, Leu S, Cheng Y, Chan J
J Formos Med Assoc
. 2022 Oct;
122(3):258-266.
PMID: 36207218
Background/purpose: Metabolic syndrome (MetS) and overactive bladder might share common pathophysiologies. Environmental fructose exposure during pre- and postnatal periods of rats may program MetS-associated bladder overactivity. We explored the dysregulated...
6.
Lin C, Su P, Huang S, Wu C, Wang H, Cheng Y, et al.
J Immunother
. 2022 Sep;
45(9):407-414.
PMID: 36121316
Immune checkpoint inhibitors (ICIs) are widely used for first-line cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC). However, whether to use ICIs as monotherapy or in combination with chemotherapy is still...
7.
Huang Y, Kang C, Lee W, Cheng Y, Chuang Y, Wang H, et al.
J Clin Med
. 2022 Aug;
11(15).
PMID: 35956069
We conduct a retrospective analysis of salvage radiotherapy plus androgen deprivation therapy (SRT+ADT) for high-risk prostate cancer patients with biochemical failure after high-intensity focused ultrasound (HIFU) as the primary treatment....
8.
Chung Y, Cheng Y, Kao Y, Tsai W, Huang G, Chen Y, et al.
Sci Rep
. 2022 Apr;
12(1):6955.
PMID: 35484165
The role of miRNAs in cancer and their possible function as therapeutic agents are interesting and needed further investigation. The miR-26a-5p had been demonstrated as a tumor suppressor in various...
9.
Lai H, Wu L, Kong P, Tsai H, Chen Y, Cheng Y, et al.
Front Oncol
. 2022 Jan;
11:828314.
PMID: 35071023
Background: The unusual high dialysis prevalence and upper urinary tract urothelial carcinoma (UTUC) incidence in Taiwan may attribute to aristolochic acid (AA), which is nephrotoxic and carcinogenic, exposure. AA can...
10.
Liu H, Kang C, Wang H, Chen C, Luo H, Chen Y, et al.
Diagnostics (Basel)
. 2021 Apr;
11(5).
PMID: 33922727
Preserving renal function and controlling oncological outcomes are pertinent when managing renal neoplasms. Cryoablation is the recommended treatment only for clinical T1a stage renal tumour. Here, we compared the outcomes...